A cross sectional analysis of 5 different markers of collagen degradation in rheumatoid arthritis

Journal of Rheumatology

Volumn 25, Issue 8, 1998, Pages 1472-1479

  St Clair, E William ^a   Moak, Susan A ^b   Wilkinson, William E ^c   Sanders, Linda ^d   Lang, Thomas ^a   Greenwald, Roberta ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^c Division of Biometry

^d Department of Medicine ^*

Author keywords

Biological markers; Collagen; Glucocorticoid therapy; Rheumatoid arthritis

Indexed keywords

COLLAGEN; DEOXYPYRIDINOLINE; PYRIDINOLINE;

ARTICLE; CARBOXY TERMINAL SEQUENCE; COLLAGEN DEGRADATION; HUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RHEUMATOID ARTHRITIS; URINE LEVEL;

AMINO ACIDS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLLAGEN; COLLAGEN TYPE I; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES; PREDNISONE;

EID: 0031880284     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Eyre DR, Paz MA, Gallop PM. Cross-linking in collagen and elastin. Ann Rev Biochem 1984;53:717-48.
2. Eyre DR. The specificity of collagen cross-links as markers of bone and connective tissue degradation. Acta Orthop Scand 1995;66 Suppl 266:166-80.
3. Poole AR, Dieppe P. Biological markers in rheumatoid arthritis. Semin Arthritis Rheum 1994;23 Suppl 2:17-31.
4. Seyedin SM, Kung VT, Daniloff YN, et al. Immunoassay for urinary pyridinoline: the new marker of bone resorption. J Bone Miner Res 1993;8:635-41.
5. Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 1994;9:1643-9.
6. Hanson DA, Weis MAE, Bollen A, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-8.
7. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994;40:2022-5.
8. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993;39:635-40.
9. Greenwald RA. Monitoring collagen degradation in arthritic patients: the search for suitable surrogates. Arthritis Rheum 1996;39:1455-65.
10. Ganero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-700.
11. Ganero P, Hausherr E, Chapuy M, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 1996;11:1531-8.
12. Schneider DL, Barrett-Connor EL. Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density. Arch Intern Med 1997;157:1241-5.
13. Garnero P, Gineyts E, Riou JP, Delmas PD. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 1994;79:780-5.
14. Ravn P, Fledelius C, Rosenquist C, Overgaard K, Christiansen C. High bone turnover is associated with low bone mass in both pre-and postmenopausal women. Bone 1996;19:291-8.
15. Uebelhart D, Gineyts E, Chapuy M, Delmas PD. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 1990;8:87-96.
16. Hassager C, Colwell A, Assiri AMA, Eastell R, Russell RGG, Christiansen C. Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross-links: a longitudinal and cross-sectional study. Clin Endocrinol 1992;37:45-50.
17. Pedrazzoni M, Alfano FS, Gatti C, et al. Acute effects of bisphosphonates on new and traditional markers of bone resorption. Calcif Tissue Int 1995;57:25-9.
18. Rosen HN, Dresner-Pollak R, Moses AC, et al. Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int 1994;54:26-9.
19. Chestnut CH III, Bell NH, Clark GS, et al. Hormone replacement therapy in menopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997;102:29-37.
20. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Applications of an enzyme immunoassay for a new marker of bone resorption (XL): follow-up on hormone replacement therapy and osteoporotic risk assessment. J Clin Endocrinol Metab 1995;80:864-8.
21. Hassager C, Jensen LT, Pødenphant J, Thomsen K, Christiansen C. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy. Calcif Tissue Int 1994;54:30-3.
22. Black D, Marabani M, Sturrock RD, Robins SP. Urinary excretion of the hydroxypyridinium cross links of collagen in patients with rheumatoid arthritis. Ann Rheum Dis 1989;48:641-4.
23. Spector TD, James IT, Hall GM, Thompson PW, Perrett D, Hart DJ. Increased levels of urinary collagen cross links in females with rheumatoid arthritis. Clin Rheumatol 1993;12:240-4.
24. Astbury C, Bird HA, McLaren AM, Robins SP. Urinary excretion of pyridinium crosslinks collagen crosslinks correlated with joint damage in arthritis. Br J Rheumatol 1994;33:11-5.
25. Gough AKS, Peel NFA, Eastell R, Holder RL, Lilley J, Emery P. Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis 1994;53:14-7.
26. Hein G, Franke S, Müller A, Bräunig E, Eidner T, Stein G. The determination of pyridinium crosslinks in urine and serum as a possible marker of cartilage degradation in rheumatoid arthritis. Clin Rheumatol 1997;16:167-72.
27. Hall GM, Spector TD, Delmas PD. Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Arthritis Rheum 1995;38:902-6.
28. Hakala M, Risteli L, Manelius J, Nieminen P, Risteli J. Increased type I collagen degradation correlates with disease severity in rheumatoid arthritis. Ann Rheum Dis 1993;52:866-9.
29. Hakala M, Aman S, Luukkainen R, et al. Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis. Ann Rheum Dis 1995;54:886-90.
30. Kotaniemi A, Isomäki, Hakala M, Risteli L, Risteli J. Increased type I collagen degradation in early rheumatoid arthritis. J Rheumatol 1994;21:1593-6.
31. St. Clair EW, Wilkinson WE, Lang T, et al. Increased expression of blood mononuclear cell nitric oxide synthetase Type 2 in rheumatoid arthritis patients. J Exp Med 1996;184:1173-8.
32. Arnett FC, Edworthy SM, Bloch DJ, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
33. Jaffe M. Uber den Niederschelag welchen Pikrinsaure in normalem Harn erzeugt and uber ein neue Reaktion des Kreatinins. Z Physiol Chem 1886;10:391-4.
34. Fleiss JL. The design and analysis of clinical expression. New York: John Wiley and Sons; 1986.
35. McLaren AM, Isdale AH, Whiting PH, Bird HA, Robins SP. Physiological variations in the urinary excretion of pyridinium crosslinks of collagen. Br J Rheumatol 1993;32:307-12.
36. Schlemmer A, Hassager C, Jensen SB, Christiansen C. Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab 1992;74:476-80.
37. Bollen A, Martin MD, Leroux BG, Eyre DR. Circadian variation in urinary excretion of bone collagen cross-links. J Bone Miner Res 1995;10:1885-90.
38. Schlemmer A, Ravn P, Hassager C, Christiansen C. Morning or evening administration of nasal calcitonin? Effects on biochemical markers of bone turnover. Bone 1997;20:63-7.
39. Sairanen S, Tähtelä R, Laitinen K, Karonen SL, Välimäki MJ. Nocturnal rise in markers of bone resorption is not abolished by bedtime calcium or calcitonin. Calcif Tissue Int 1994;53:349-52.
40. Takahashi M, Kushida K, Ohishi T, et al. Quantitative analysis of crosslinks pyridinoline and pentosidine in articular cartilage of patients with bone and joint disorders. Arthritis Rheum 1994;37:724-8.
41. Lems WF, Jacobs JWG, Van den Brink HR, Van Rijn HJM, Bijlsma JWJ. Transient decrease in osteocalcin and markers of type I collagen turnover during high-dose corticosteroid pulse therapy in rheumatoid arthritis. Br J Rheumatol 1993;32:787-9.
42. Lems WF, Gerrits MI, Jacobs JWG, van Vugt RM, van Rijn HJM, Bijlsma JWJ. Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann Rheum Dis 1996;55:288-93.
43. Kollerup G, Hansen M, Horsley-Petersen K. Urinary hydroxypyridinium cross-links of collagen in rheumatoid arthritis: relation to disease activity and effects of methylprednisolone. Br J Rheumatol 1994;33:816-20.
44. Conti A, Sartorio A, Ferrero S, Ambrosi B. Modifications of biochemical markers of bone and collagen turnover during corticosteroid therapy. J Endocrinol Invest 1996;19:127-30.
45. Paimela L, Leirisalo-Repo M, Risteli L, Hakala M, Helve T, Risteli J. Type I collagen degradation product in serum of patients with early rheumatoid arthritis: relationship to disease activity and radiological progression in a 3-year follow-up. Br J Rheumatol 1994;33:1012-6.